Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278213 | 0.84 | MEN1 (0.34) | RAB9AHSD17B10MAPK14KDM4E | |
| SCHEMBL3512912 | 0.79 | RAB9A (0.33) | RAB9AHSD17B10MAPK14 | |
| SCHEMBL12452873 | 0.77 | KDM4E (0.43) | RAB9AHSD17B10MAPK14KDM4E | |
| SCHEMBL14995669 | 0.74 | NUDT1 (0.46) | HSD17B10 | |
| SCHEMBL305093 | 0.74 | GABRA1 (0.43) | HSD17B10KDM4EHMGCRHRH4 | |
| SCHEMBL37832 | 0.74 | ALDH1A1 (0.40) | HSD17B10KDM4EHMGCRHRH4 | |
| SCHEMBL12452877 | 0.73 | NOTUM (0.44) | HSD17B10MAPK14KDM4E | |
| Bromide SCHEMBL10759230 | 0.72 | HSD17B10 (0.39) | HSD17B10KDM4EHMGCRHRH4 | |
| Hydrochloric Acid SCHEMBL31414207 | 0.72 | POLB (0.44) | HSD17B10KDM4EHMGCRHRH4 | |
| SCHEMBL22543799 | 0.72 | HSD17B10 (0.39) | HSD17B10KDM4EHMGCRHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | CANON KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| WO-2016174813-A1 | 2,2'-BIBENZO[D]IMIDAZOLIDENE COMPOUND HAVING HETEROMONOCYCLIC GROUPS AT THE 1-, 1'-, 3- AND 3'-POSITIONS, AND ORGANIC LIGHT-EMITTING ELEMENT AND DISPLAY DEVICE CONTAINING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | BRD1, DRD1, NR2E3 | RAB9A 1281/4885HSD17B10 2105/4885MAPK14 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.